课题基金 / 基金详情

Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis

Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis
早期体内表达的抗原及其在球孢子菌病毒力、免疫反应和疫苗中的作用
批准号:
10689664
负责人:
Paul Stephen Keim
金额:
$25.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-08-24 至 2027-07-31

项目摘要

项目成果

Paul Stephen Keim的其他基金

相似基金

相关文献

中文摘要
翻译
行政核心科室 摘要 毒力、免疫反应和疫苗(VIRV)Cocci合作研究中心(CCRC) 由行政核心(ADC)和一个高级管理团队(SMT)领导。SMT由以下部分组成 保罗·凯姆博士(整体PI/PD)、布里奇特·巴克、黛博拉·富勒和埃里克·塞特尔斯--他们都有丰富的科学经验 项目经理。这是北亚利桑那大学、华盛顿大学、 亚利桑那大学、克恩医学中心、杜兰国家灵长类动物研究中心和 翻译基因组研究所,将利用每个机构的优势,并将 协同促进协作和富有成效的科学文化。因为它是一个多机构的 计划、协调和沟通是必不可少的,也将是ADC的重点。所有的 个别核心和研究项目(RP)将在SMT上代表,这将提供有效的 纵向和横向的沟通、管理。每周一次的会议将在每个 CCRC组件除了每月定期举行的CCRC交叉会议外,还将促进参与和 跨项目协作。所有会议都将通过视频会议提供支持并进行录音,以 降低物理研究地点的参与门槛。闲置的客户和渠道将是一个 管理沟通方案的重要组成部分。财务和合规监控,以及 核心和区域方案的报告活动将由ADC管理,其中包括一名项目经理 有了商业会计支持。主要服务,如出版、动物模型和旅游 通过核心提供资金,以支持三个单独的区域方案。将生成里程碑和时间表 针对每个组件,并在SMT会议期间每月进行审查。将评估外展活动 并且是成功衡量标准的一部分。作为这些CCRC协调努力的组成部分,我们将在 发展研究项目(DRP),将培养早期职业教师,跨CCRC参与,以及 创新的想法。ADC将在整个生命周期内征集、评估、授予和监督DRP VIRV-CCRC。外展将包括我们的虚拟研讨会计划和在线论坛,以支持硅谷 发烧临床和研究社区,特别是其他NIAID CCRC的。专业发展, 将鼓励对学生、博士后研究员和初级教师进行培训和指导,并 由ADC支持。将培育NIAID Cocci中心内和之间的科学工作组 与研讨会系列、旅行基金和联合试点项目。VIRV-CCRC团队成员将 预计将进行广泛合作,并产生相关和有影响力的科学产品,包括 一种潜在的准备进行临床试验的新型疫苗。
英文摘要
Administrative Core Section SUMMARY The Virulence, Immune Response, and Vaccine (VIRV) Cocci Cooperative Research Center (CCRC) will be directed by the administrative core (AdC) and a senior management team (SMT). The SMT is composed of Drs. Paul Keim (overall PI/PD), Bridget Barker, Deborah Fuller, and Erik Settles – all experienced scientific project managers. This is an aggregate effort by Northern Arizona University, University of Washington, the University of Arizona, the Kern Medical Center, the Tulane National Primate Research Center, and the Translational Genomics Research Institute that will capitalize upon the strengths of each institution and will synergistically foster a collaborative and productive scientific culture. Because it is a multi-Institutional program, coordination and communication are essential and will be an emphasis in the AdC. All of the individual Cores and Research Projects (RPs) will be represented on the SMT, which will provide effective vertical and horizontal communication, and management. Weekly meetings will be held within each of the CCRC components in addition to regular monthly cross-CCRC sessions to foster engagement and collaboration across the projects. All meetings will be supported by video conferencing and recorded, to lower participation barriers across the physical research locations. Slack accounts and channels will be an important part of the management communication scheme. Financial and compliance monitoring, along with reporting activities of the Cores and RPs, will be managed by the AdC, which includes a project manager with business accounting support. Major services, such as publication, animal models, and travel will be funded through the Cores to support the three individual RPs. Milestones and Timelines will be generated for each component and reviewed monthly during the SMT meetings. Outreach activities will be assessed and are part of the success metrics. Integral to these CCRC coordination efforts will be our program in Development Research Projects (DRPs) that will foster early career faculty, cross CCRC participation, and innovative ideas. The AdC will solicit, evaluate, award, and monitor the DRPs throughout the life of the VIRV-CCRC. Outreach will include our virtual seminar program and online forums to support the Valley Fever clinical and research communities, particular to other NIAID CCRC’s. Professional development, training, and mentoring of students, postdoctoral fellows, and junior faculty will be encouraged and supported by the AdC. Scientific working groups within and across the NIAID Cocci Centers will be fostered with the seminar series, travel funds, and joint pilot projects. The VIRV-CCRC team members will be expected to collaborate extensively and to produce relevant and impactful scientific products, including potentially a novel vaccine ready for clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis
  • 批准号:
    10689662
  • 项目类别:
  • 资助金额:
    $154.27万
  • 财政年份:
    2022
  • 负责人:
    Paul Stephen Keim
  • 依托单位:
Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis
  • 批准号:
    10356626
  • 项目类别:
  • 资助金额:
    $26.49万
  • 财政年份:
    2022
  • 负责人:
    Paul Stephen Keim
  • 依托单位:
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis
  • 批准号:
    10356625
  • 项目类别:
  • 资助金额:
    $151.91万
  • 财政年份:
    2022
  • 负责人:
    Paul Stephen Keim
  • 依托单位:
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis
  • 批准号:
    10891793
  • 项目类别:
  • 资助金额:
    $139.02万
  • 财政年份:
    2022
  • 负责人:
    Paul Stephen Keim
  • 依托单位:
海外基金